These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 35868965

  • 1. Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.
    Gardiner BJ, Lee SJ, Robertson AN, Cristiano Y, Snell GI, Morrissey CO, Peleg AY, Westall GP.
    J Heart Lung Transplant; 2022 Sep; 41(9):1258-1267. PubMed ID: 35868965
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
    Dioverti MV, Bhaimia E, Yetmar ZA, Melendez DP, Misner L, Beito E, Deziel PJ, Theel ES, Razonable RR.
    Clin Transplant; 2023 Dec 16; 37(12):e15143. PubMed ID: 37805968
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 16; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 5. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM.
    Transpl Infect Dis; 2020 Aug 16; 22(4):e13277. PubMed ID: 32170813
    [Abstract] [Full Text] [Related]

  • 6. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C, Preiksaitis JK, Cervera C, University of Alberta Cardiothoracic Transplant GroupDivision of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada..
    Transpl Infect Dis; 2019 Feb 16; 21(1):e13015. PubMed ID: 30358023
    [Abstract] [Full Text] [Related]

  • 7. Reliability of QuantiFERON®-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.
    Sermet K, Goeminne C, Hantz S, Assaf A, Faure E, Lazrek M, Faure K, Alain S, Vuotto F.
    Clin Transplant; 2023 Dec 16; 37(12):e15109. PubMed ID: 37641575
    [Abstract] [Full Text] [Related]

  • 8. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C, Preiksaitis J, Cervera C, University of Alberta Cardiothoracic Transplant Group.
    Transpl Infect Dis; 2018 Oct 16; 20(5):e12964. PubMed ID: 29981174
    [Abstract] [Full Text] [Related]

  • 9. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
    Tarasewicz A, Dębska-Ślizień A, Rutkowski B.
    Transplant Proc; 2016 Jun 16; 48(5):1650-3. PubMed ID: 27496465
    [Abstract] [Full Text] [Related]

  • 10. Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus.
    Servais AM, McMullen JS, Bowen R, Kleiboeker SB, Ulloa I, Duncan K, Miles CD.
    Transpl Infect Dis; 2024 Aug 16; 26(4):e14291. PubMed ID: 38708965
    [Abstract] [Full Text] [Related]

  • 11. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.
    Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, Peleg AY, Snell GI.
    Transplantation; 2019 May 16; 103(5):1005-1013. PubMed ID: 30247316
    [Abstract] [Full Text] [Related]

  • 12. Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.
    Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP.
    Transpl Infect Dis; 2020 Jun 16; 22(3):e13255. PubMed ID: 32020736
    [Abstract] [Full Text] [Related]

  • 13. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 14. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients.
    Martinez S, Sindu D, Nailor MD, Cherrier L, Tokman S, Walia R, Goodlet KJ.
    Transpl Infect Dis; 2024 Jun 15; 26(3):e14279. PubMed ID: 38742601
    [Abstract] [Full Text] [Related]

  • 15. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA, Brennan DC, Saeed MJ, Fraser VJ, Olsen MA.
    Clin Transplant; 2016 Apr 15; 30(4):435-44. PubMed ID: 26841129
    [Abstract] [Full Text] [Related]

  • 16. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K, Mitro G, Buschor K, Rees M, Ortiz J.
    Transpl Immunol; 2019 Oct 15; 56():101226. PubMed ID: 31344441
    [Abstract] [Full Text] [Related]

  • 17. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP.
    JAMA; 2020 Apr 14; 323(14):1378-1387. PubMed ID: 32286644
    [Abstract] [Full Text] [Related]

  • 18. Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients.
    Gardiner BJ, Bailey JP, Percival MA, Morgan BA, Warner VM, Lee SJ, Morrissey CO, Kaye DM, Peleg AY, Taylor AJ.
    Clin Transplant; 2023 Jun 14; 37(6):e14982. PubMed ID: 36988473
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.
    J Heart Lung Transplant; 2010 Sep 14; 29(9):1014-20. PubMed ID: 20598582
    [Abstract] [Full Text] [Related]

  • 20. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
    Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, Hauser IA, Alshuth U, Kliem V.
    Transplantation; 2018 May 14; 102(5):876-882. PubMed ID: 29166336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.